zamicastat
Small moleculeexperimental
Clinical trial activity
15 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
13
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2011 (NCT02151994)
Timeline
Indications
Mechanism of action
- Dopamine beta-hydroxylaseINHIBITOR
DBH inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Fc1cc(F)c2c(c1)C[C@@H](n1c(CCNCc3ccccc3)c[nH]c1=S)CO2- Mol. weight
- 401.48 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594440 ↗
Also known as
- bia 5-1058
- yh22189
- zamicastat
- zamicastat
- zamicastat
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06009185 | Phase 2 | Jun 26, 2019 | Bial |
| NCT04316143 | Phase 2 | Jun 6, 2019 | Bial |
| NCT04069130 | Phase 1 | Apr 8, 2019 | Bial |
| NCT03708146 | Phase 1 | Jun 24, 2018 | Bial |
| NCT07173738 | Phase 1 | Jun 11, 2018 | Bial, Simbec-Orion |
| NCT03489005 | Phase 1 | Apr 30, 2018 | Bial, Covance |
| NCT04994860 | Phase 1 | Mar 22, 2018 | Bial |
| NCT04675944 | Phase 1 | Feb 28, 2018 | Bial |
| NCT04994119 | Phase 1 | Feb 23, 2018 | Bial |
| NCT04991207 | Phase 1 | Feb 6, 2018 | Bial |
| NCT04991181 | Phase 1 | Mar 31, 2017 | Bial |
| NCT02608242 | Phase 1 | Nov 1, 2015 | Yuhan Pharmaceutical Company |
| NCT04991194 | Phase 1 | Oct 12, 2015 | Bial |
| NCT04991155 | Phase 1 | Jul 20, 2015 | Bial |
| NCT02151994 | Phase 1 | Mar 1, 2011 | Bial |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bial | For profit | 14 | 14 | 2 | 2011 |
| Covance | For profit | 1 | 0 | 1 | 2018 |
| Simbec-Orion | For profit | 1 | 0 | 1 | 2018 |
| Yuhan Pharmaceutical Company | For profit | 1 | 1 | 1 | 2015 |
4 organizations
Page 1 / 1